富氢液联合羟考酮控释片对癌性神经病理性疼痛的临床疗效观察

Clinical Assessment of Hydrogen-rich Water and Oxycodone Hydrochloride Controlled release Tablets in Treatment of Malignant Neuropathic Pain

目的:探讨富氢液(HRW)联合盐酸羟考酮控释片(OHCT)对癌性神经病理性疼痛(MNP)的临床疗效。方法:选择80例MNP患者随机分成OHCT治疗组(A组)和HRW联合OHCT治疗组(B组),观察两组患者的VAS评分、爆发痛情况、疼痛缓解率、OHCT用量及药物不良反应。结果:用药治疗后两组患者的VAS评分和爆发痛发作次数均较治疗前显著降低(P<0.05);在治疗第14 d和28 d后VAS评分、疼痛缓解率、爆发痛发作次数及OHCT用量等方面B组比A组患者改善更明显(P<0.05),且便秘、恶心和呕吐等不良反应明显减少(P<0.05)。结论:HRW联合OHCT治疗能更有效改善MNP临床症状,并减少OHCT用量及药物不良反应。

Objective： To investigate the clinical efficacy of hydrogen- rich water（ HRW） combined with oxycodone hydrochloride controlled- release tablets（ OHCT） in the treatment of malignant neuropathic pain（ MNP） patients. Methods： Eighty MNP patients were randomly divided into two groups： OHCT group（ group A） and HRW combined OHCT group（ group B）. The visual analog scale（ VAS） score,frequency of pain outbreaks,pain relief rate,average dose of OHCT per day,and adverse reactions were observed. Results： The VAS scores and frequency of pain outbreaks in groups A and B were significantly reduced after treatment（ P〈0. 05）. Compared with group A,the VAS scores,pain relief rate,outbreak pain and average dose of OHCT per day in group B were significantly improved after 14 and 28 days of treatment（ P〈0. 05）,and the adverse reactions,such as constipation,nausea and vomiting,in group B were significantly less than those in group A（ P〈0. 05）. Conclusion： HRW combined with OHCT can effectively improve the MNP,and reduce average dose of OHCT per day and adverse reactions.